Federal Register / Vol. 75, No. 47 / Thursday, March 11, 2010 / Notices 11551 

Dated: March 8, 2010. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2010–5275 Filed 3–10–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Advisory Committee for 

Pharmaceutical Science and Clinical 

Pharmacology; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Advisory 

Committee for Pharmaceutical Science 

and Clinical Pharmacology. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on April 14, 2010, from 8 a.m. to 

5 p.m. 

Location: Hilton Washington DC/ 

Silver Spring, The Ballrooms, 8727 

Colesville Rd., Silver Spring, MD. The 

hotel phone number is 301–589–5200. 

Contact Person: Anuja Patel, Center 

for Drug Evaluation and Research (HFD– 

21), Food and Drug Administration, 

5600 Fishers Lane (for express delivery, 

5630 Fishers Lane, rm. 1093) Rockville, 

MD 20857, 301–827–7001, FAX: 301– 

827–6776, e-mail: 

Anuja.Patel@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512539. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On April 14, 2010, the 

committee will: (1) Receive 

presentations from the Office of Generic 

Drugs (OGD) on a proposal for revision 

of the bioequivalence (BE) approaches, 

specifically to discuss the addition of a 

limitation on point estimates; (2) receive 

presentations on an awareness topic to 

highlight some issues associated with 

product instability (failure of a marketed 

product to meet stability specifications 

through the expiration date), and the 

potential research needs to address 

those issues; and (3) receive and discuss 

presentations from Office of 

Pharmaceutical Science (OPS) on the 

regulatory challenges of drug-induced 

phospholipidosis (excessive 

intracellular accumulation of 

phospholipids, a kind of fatty molecule, 

due to the use of certain drugs). 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before March 30, 2010. 

Oral presentations from the public will 

be scheduled between approximately 1 

p.m. and 2 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before March 22, 2010. Time allotted 

for each presentation may be limited. If 

the number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by March 23, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Anuja Patel 

at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: March 8, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–5264 Filed 3–10–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Advisory Eye Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Eye Council. 

Date: June 17, 2010. 

Closed: 8:30 a.m. to 11 a.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: Melrose Hotel, 2430 Pennsylvania 

Ave., NW., Washington, DC 20037. 

Open: 11 a.m. to 5 p.m. 

Agenda: Following opening remarks by the 

Director, NEI, there will be presentations by 


jlentini on DSKJ8SOYB1PROD with NOTICES
11552 Federal Register / Vol. 75, No. 47 / Thursday, March 11, 2010 / Notices 

the staff of the Institute and discussions 

concerning Institute programs. 

Place: Melrose Hotel, 2430 Pennsylvania 

Ave., NW., Washington, DC 20037. 

Contact Person: Andrew P. Mariani, PhD, 

Executive Secretary, National Advisory Eye 

Council, Division of Extramural Research, 

National Eye Institute, National Institutes of 

Health, Bethesda, MD 20892, (301) 451–2020, 

apm@nei.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nei.nih.gov, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: March 4, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–5175 Filed 3–10–10; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal in formation concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of person al privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel Clinical 

Coordinating Support for NIDA Center for 

Clinical Trials Network (CCTN) (2221). 

Date: April 6, 2010. 

Time: 9 a.m. to 2 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Courtyard by Marriott Rockville, 

2500 Research Boulevard, Rockville, MD 

20850. 

Contact Person: Lyle Furr, Contract Review 

Specialist, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 220, MSC 8401, 6101 Executive 

Boulevard, Bethesda, MD 20892–8401, (301) 

435–1439, 1f33c.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel Clinical 

Worlds: Enhancing Substance Abuse 

Provider Training Through Emerging 

Technologies (5544). 

Date: April 27, 2010. 

Time: 9:30 a.m. to 12 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852. 

Contact Person: Lyle Furr, Contract Review 

Specialist, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 220, MSC 8401, 6101 Executive 

Boulevard, Bethesda, MD 20892–8401, (301) 

435–1439, 1f33c.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel Drug 

Scene Investigation Science (1138). 

Date: April 28, 2010. 

Time: 9:30 a.m. to 12 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852. 

Contact Person: Lyle Furr, Contract Review 

Specialist, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 220, MSC 8401, 6101 Executive 

Boulevard, Bethesda, MD 20892–8401, (301) 

435–1439, 1f33c.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: March 4, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–5171 Filed 3–10–10; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HOMELAND 

SECURITY 

Transportation Security Administration 

Intent To Request Renewal From OMB 

of One Current Public Collection of 

Information: Aviation Security 

Customer Satisfaction Performance 

Measurement Passenger Survey 

AGENCY: Transportation Security 

Administration, DHS. 

ACTION: 60 day notice. 

SUMMARY: The Transportation Security 

Administration (TSA) invites public 

comment on one currently approved 

Information Collection Request (ICR), 

OMB control number 1652–0013, 

abstracted below, that we will submit to 

the Office of Management and Budget 

(OMB) for renewal and amendment in 

compliance with the Paperwork 

Reduction Act. The ICR describes the 

nature of the information collection and 

its expected burden. The collection 

involves surveying travelers to measure 

customer satisfaction of aviation 

security in an effort to more efficiently 

manage airport performance. 

DATES: Send your comments by May 10, 

2010. 

ADDRESSES: Comments may be emailed 

to TSAPRA@dhs.gov or delivered to the 

TSA Paperwork Reduction Act (PRA) 

Officer, Office of Information 

Technology (OIT), TSA–40, 

Transportation Security Administration, 

601 South 12th Street, Arlington, VA 

20598–6040. 

FOR FURTHER INFORMATION CONTACT: 

Joanna Johnson at the above address, or 

by telephone (571) 227–3651. 

SUPPLEMENTARY INFORMATION: 

Comments Invited 

In accordance with the Paperwork 

Reduction Act of 1995 (44 U.S.C. 3501 

et seq.), an agency may not conduct or 

sponsor, and a person is not required to 

respond to, a collection of information 

unless it displays a valid OMB control 

number. The ICR documentation is 

available at http://www.reginfo.gov. 

Therefore, in preparation for OMB 

review and approval of the following 

information collection, TSA is soliciting 

comments to— 

(1) Evaluate whether the proposed 

information requirement is necessary for 

the proper performance of the functions 

of the agency, including whether the 

information will have practical utility; 

(2) Evaluate the accuracy of the 

agency’s estimate of the burden; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

(4) Minimize the burden of the 

collection of information on those who 

are to respond, including using 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Information Collection Requirement 

OMB Control Number 1652–0013; 

Aviation Security Customer Satisfaction 

Performance Measurement Passenger 

Survey. TSA, with OMB’s approval, has 

conducted surveys of passengers and 

now seeks approval to continue this 

effort. TSA plans to conduct passenger 

surveys at airports nationwide. The 

surveys will be administered using an 

intercept methodology. The intercept 

methodology uses TSA personnel who 

are not in uniform to hand deliver paper 

survey forms to passengers immediately 

following the passenger’s experience 

with the TSA’s checkpoint security 


jlentini on DSKJ8SOYB1PROD with NOTICES